Triphenylphosphine oxide, or TPPO, had a settled reputation. It was regarded as a selective inhibitor of the ion channel TRPM5, with no activity against its close relative TRPM4. Tested under ordinary laboratory conditions, it did nothing to TRPM4, and that was the end of it.
Northwestern University researchers ran it again at 37 degrees Celsius, human body temperature, with calcium present at levels that actually exist inside a cell. The supposedly inactive compound became a potent activator of the channel.
Then they found the reverse. A known TRPM4 activator, Necrocide-1, opened the channel in the absence of calcium, as expected, and was antagonized when calcium levels rose.
The Two Variables Nobody Was Controlling For
The study, published in Nature Structural and Molecular Biology, was led by Wei Lü and Juan Du, professors of molecular biosciences at Northwestern's Weinberg College and professors of pharmacology at the Feinberg School of Medicine. Postdoctoral fellow Jinhong Hu is the first author. An earlier preprint version appeared on bioRxiv.
Early-stage drug evaluation is often conducted at room temperature in simplified buffers, and structural work is even colder. For decades, scientists have imaged protein structures between 4 and 18 degrees Celsius to stabilize samples. That is a practical choice, not a biological one, and it is roughly 20 degrees below the body temperature at which those proteins operate.
"We found that temperature really matters," Lü said in a statement from Northwestern Medicine. "If you continue to use very simplified experimental conditions, you may miss opportunities to identify useful drug molecules, or even misunderstand how they work."
Calcium turned out to matter at concentrations most people would dismiss as negligible. Even at around 100 nanomolar, the ion significantly influenced how molecules interacted with the protein. "Even though that's a very low concentration, it has a major impact on how ligand binding happens," Lü said.
What Cryo-EM Showed, and What It Did Not
To understand the mechanism, the team used cryo-electron microscopy to image TRPM4 at near-atomic resolution under different conditions, comparing conventional laboratory settings with those that mimic physiological conditions.
Proteins adopted different shapes at body temperature. But the more useful finding is subtler than a pocket simply opening up. The journal's own summary of the work notes that hidden ligand activities were missed under simplified assay conditions even at structurally stable sites, meaning a visible change in the binding pocket is not the whole explanation. Temperature, calcium, and ligand binding worked in synergy rather than through one tidy conformational switch.
Not every compound behaved this way. Two inhibitors, NBA and CBA, engaged a nearby pocket and consistently blocked the channel, regardless of temperature, locking it in a non-conductive pre-open state. The lesson is not that all lab results are wrong, but that condition dependence is a variable that has largely gone unmeasured and that it varies compound by compound rather than applying uniformly.
That distinction matters for how the finding should be used. A screening result is not a fixed property of a molecule. It is a measurement of a molecule under one set of conditions, and in this system, the conditions were doing more work than anyone had assumed.
"This overturns what we thought about this compound," Lü said of TPPO. "It wasn't inactive; it just needed the right physiological context."
An Odd Opportunity Hiding in the Failure
If a compound's effect depends on calcium, that dependence is something to design for rather than around.
Intracellular calcium is tightly regulated and rises under particular cellular conditions. A compound engineered to act only above a calcium threshold would, in principle, stay quiet elsewhere and switch on where that signature exists. That is a potential route to selectivity that does not require the target protein itself to be unique to diseased tissue. It is a design idea this study makes plausible, not one it demonstrates.
TRPM4 is not an obscure target. The paper describes it as an ion channel implicated in cardiac conduction, immune regulation, cancer, and intestinal fluid homeostasis, and notes that several small-molecule TRPM4 modulators are already available as research tools.
What This Does Not Establish
No patient is affected by this finding today. No compound was tested in an animal, no candidate was advanced into a clinical program, and the work does not show that any specific shelved molecule would succeed in humans.
The claim that similar hidden effects exist across many other targets is an extrapolation from one protein, and the authors present it that way.
"This completely overturned what we thought we knew," Du said in the university's announcement. "It shows that we may be overlooking important drug candidates simply because we are not testing them under the right conditions."
The team's ambitions extend beyond a single channel. "This is not just for TRPM4," Du said. "All proteins function in the human body under physiological conditions, temperature, ions, and lipids, and they can all be affected." The team's next step is to screen additional compounds against TRPM4 under physiological conditions and apply the same approach to other disease-related proteins, while also examining membrane lipids as an additional context variable.
Anyone taking a prescribed medication should not read this as a reason to question their treatment. Approved drugs have been tested in human bodies at human body temperature, which is exactly the condition this research argues for.
Key Questions Answered
What did the researchers find?
Body temperature and intracellular calcium can dramatically change how compounds interact with the TRPM4 protein, in some cases reversing a compound's apparent effect.
What is TPPO?
Triphenylphosphine oxide, a small synthetic molecule previously regarded as a selective TRPM5 inhibitor with no activity against TRPM4. It is not an approved drug.
Why are drugs tested at room temperature?
It is practical and reproducible. The study argues that convenience has been quietly costing accuracy.
How much calcium made a difference?
At levels around 100 nanomolar, a very low concentration, the binding of molecules to the channel changed meaningfully.
What is TRPM4?
An ion channel the paper describes as implicated in cardiac conduction, immune regulation, cancer, and intestinal fluid homeostasis.
Does this mean rejected drugs will be revived?
Not automatically. It means some screening results may have been produced under conditions that hid activity, which would need to be tested case by case.
Does this affect the medications I take?
No. Approved drugs have already been evaluated in human patients under real physiological conditions.
